32 reports

  • Allergy Drugs Sales Volume
  • Allergy Drugs Companies in China

Chart ##: China' s Allergy Drugs Sales Volume (Billion Yuan) INTRODUCTION Chapter I Allergy Drugs Industry Structure CHAPTER III ALLERGY DRUGS INDUSTRY ASSESSMENTS Since 2009, allergy drugs consumption has been growi

  • Allergy Drug
  • China
  • Eisai Co., Ltd.
  • Sanofi-Synthelabo Inc.
  • Schering-Plough China Inc.
  • Allergy Drugs Markets in China
  • Allergy Drugs Industry Structure

The allergy drugs industry is one of key sectors of Chinese industry and has become more and more important.

  • Allergy Drug
  • China
  • Demand
  • Eisai Co., Ltd.
  • Schering-Plough China Inc.
  • ALLERGY DRUGS IMPORT (BILLION YUAN)
  • ALLERGY DRUGS EXPORT (BILLION YUAN)

The WHO has allready ranked the Allergy as one of the Chapter IV ALLERGY DRUGS PRODUCTION AND DEMAND three diseases that need more research, prevention and cure.

  • Allergy Drug
  • China
  • Demand
  • Market Size
  • Trade
  • 5.2.1 ANTI-ALLERGY DRUGS
  • BY ANTI-ALLERGY DRUGS

The 2018 ACAAI data also states that, across the world, adverse drug reactions may affect up to one-tenth of the world' s population and affect up to one-fifth of all hospitalized patients.

  • Allergy Drug
  • Company
  • Market Segment
  • Market Size
  • F. Hoffmann-La Roche Ltd.

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Drug
  • Allergy Immunotherapy
  • Therapy
  • Biomay AG

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Drug
  • Allergy Immunotherapy
  • Therapy
  • Biomay AG
  • STANDARDIZED MITE (DERMATOPHAGOIDES PTERONYSSINUS + DERMATOPHAGOIDES FARINAE) ALLERGEN EXTRACT - DRUG PROFILE

" House dust mite allergy is one of the most common allergies, impacting the quality of life for patients across ages and geographies.

  • Allergy Drug
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • STANDARDIZED MITE (DERMATOPHAGOIDES PTERONYSSINUS + DERMATOPHAGOIDES FARINAE) ALLERGEN EXTRACT - DRUG PROFILE

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Allergy Drug
  • Medical Biotechnology
  • United States
  • World
  • Product Initiative
  • ALLERGEN FOR ALLERGIC RHINITIS, ALLERGIC RHINO-CONJUNCTIVITIS AND BIRCH POLLEN ALLERGY - DRUG PROFILE
  • ALLERGEN FOR ALLERGIC RHINITIS AND RHINOCONJUNCTIVITIS - DRUG PROFILE

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy Drug
  • Eye Disease
  • Ophthalmic Solution
  • Pharmaceutical
  • Product Initiative
  • ALLERGEN FOR ALLERGIC RHINITIS, ALLERGIC RHINO-CONJUNCTIVITIS AND BIRCH POLLEN ALLERGY - DRUG PROFILE
  • ALLERGEN FOR ALLERGIC RHINITIS, ALLERGIC RHINO-CONJUNCTIVITIS AND BIRCH POLLEN ALLERGY

Oneness Biotech Co Ltd (Oneness Biotech) is a biopharmaceutical company that conducts research and development of drugs.

  • Allergy Drug
  • Allergy Immunotherapy
  • Respiratory Disease
  • Therapy
  • Glenmark Pharmaceuticals Ltd.

Drug Allergy- The allergy from medicines, drugs is the most common form of allergy.

  • Allergy Drug
  • Respiratory Disease
  • World
  • Merck & Co., Inc.
  • Stallergenes Greer plc

Anti-Allergy Drugs ##. ##. ##.

  • Allergy Drug
  • OTC
  • APAC
  • World
  • Market Size

Allergy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 ##.

  • Allergy Drug
  • APAC
  • World
  • Forecast
  • Market Size
  • ALLERGEN FOR ALLERGIC RHINITIS, ALLERGIC RHINO-CONJUNCTIVITIS AND BIRCH POLLEN ALLERGY - DRUG PROFILE
  • Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Birch Pollen Allergy

The drug candidate activates allergen-specific T-helper type ## (Th##) cellular responses with the production of interferons by antigen presenting cells (APC), natural killer cells (NK), and T cells.

  • Allergy Drug
  • Eye Disease
  • Ophthalmic Solution
  • Pharmaceutical
  • Allergy Therapeutics plc

High capital intensity is more than $##. ## of capital to $## of labor; medium is $##. ## to $##. ## of capital to $## of labor; low is less than $##. ## of capital for every $## of labor.

  • Allergy Drug
  • United States
  • Demand
  • Forecast
  • Trade
  • Sep 28, 2016: Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan
  • Chronic Urticaria Or Hives - Product Development Milestones

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Allergy Drug
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • HEADACHE, NASOPHARYNGITIS, BRONCHITIS, SINUSITIS, FATIGUE AND ASTHMA.
  • BILASTINE - DRUG PROFILE

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Allergy Drug
  • Dermatological Condition
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial profile. 65 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Drug/ Molecule refers to Primary Intervention only. ##.

  • Allergy Drug
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Allergy Drug
  • OTC
  • Therapy
  • World
  • Product Initiative

ALLERGIES THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* PROMINENT DRUGS ALLERGIES THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* ALLERGIES THERAPEUTICS CLINICAL TR

  • Allergy Drug
  • Clinical Trial
  • Pharmaceutical
  • Japan
  • World

TYPE I HYPERSENSITIVITY THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* PROMINENT DRUGS TYPE I HYPERSENSITIVITY THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* TYPE I HYPERSENSITIVITY THERAPEUT

  • Allergy
  • Allergy Drug
  • Clinical Trial
  • Pharmaceutical
  • World
  • Clinical Trial profile. 307 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

DRUG/ MOLECULE REFERS TO PRIMARY INTERVENTION ONLY. ##.

  • Allergy Drug
  • Clinical Trial
  • Molecular Diagnostics
  • Pharmaceutical
  • World
  • 8.3.1 FEATURED NEWS & PRESS RELEASES

Anti-allergy Drug in Japan Bilanoa Tablets, an Oral Anti-allergy Drug in Japan TAIHO HAS FURTHER DEVELOPED THE DRUG AFTER SIGNING A LICENSE AGREEMENT WITH FAES FARMA IN JULY 2012 FOR THE DEVELOPMENT AND MARKETING RIGHTS IN JAPAN.

  • Allergy Drug
  • Dermatological Condition
  • Therapy
  • Company
  • Product Initiative

HYPERSENSITIVITY THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017* PROMINENT DRUGS HYPERSENSITIVITY THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017* HYPERSENSITIVITY THERAPEUTICS CLINICAL TRIALS,

  • Allergy Drug
  • Clinical Trial
  • Pharmaceutical
  • Japan
  • World
  • Perennial Allergic Rhinitis - Therapeutics Assessment

INS products such as Nasacort Allergy ##HRTM are recommended as the most effective drugs for the treatment of allergic rhinitis##.

  • Allergy Drug
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Pfizer Inc.
  • BILASTINE - DRUG PROFILE

Seasonal Allergic Rhinitis Overview PIPELINE PRODUCTS FOR SEASONAL ALLERGIC RHINITIS - OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR SEASONAL ALLERGIC RHINITIS, H## 2016 Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR SEASONAL ALLERGIC RHINITIS, H## 2016 Source: Global M

  • Allergy Drug
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Pfizer Inc.

In addition, by a vote of ## to one, with one abstention, the Committee recommended self-administration of the drug by patients.

  • Allergy Drug
  • Europe
  • United States
  • World
  • Product Initiative
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Allergy Drug
  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • World

(France) ##.

  • Allergy Drug
  • Medical Biotechnology
  • United States
  • World
  • Market Shares
  • R&D Progress

Adamis and Beximco intend to introduce a number of separate drugs into the U. S. over the next years in the allergy and respiratory areas and may co-develop certain drugs.

  • Allergy Drug
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Pfizer Inc.